Tirzepatide helps lower body weight, cardiovascular risk in diabetics
Tirzepatide is a dual Glucose-dependent Insulinotropic Polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes.
A new study by Prof Stefano Del Prato, MD and team has revealed that in people with type 2 diabetes and elevated cardiovascular risk, tirzepatide, showed greater efficacy than glargine in HbA1c reduction with a lower incidence of hypoglycaemia at 52 weeks.
For more details, check out the full story on the link below:
Tirzepatide Bests Insulin Glargine In Lowering A1C, Body Weight And CV Risk In Diabetics: Lancet
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd